MedTrace Logo

Comparing Liposomal Bupivacaine Versus Standard Bupivacaine in Colorectal Surgery

NCT03702621 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-05-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the difference between two different pain control methods in patients who will be having a colorectal surgery

Conditions

  • Colorectal Surgery

Interventions

DRUG

liposomal Bupivacaine

20 mL liposomal bupivacaine are injected into the liposomal bupivacaine group

DRUG

Bupivacaine Hydrochloride

40 mL of 0.125% bupivacaine hydrochloride are injected into the liposomal bupivacaine group. 60mL of 0.25% bupivacaine hydrochloride are injected into the standard bupivacaine group

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • Yar Yeap, MD · Indiana University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-30
Primary Completion
2020-03-13
Completion
2020-03-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03702621 on ClinicalTrials.gov